Changing clinical practice: extending the benefits of adjuvant endocrine therapy in breast cancer.

@article{Goss2004ChangingCP,
  title={Changing clinical practice: extending the benefits of adjuvant endocrine therapy in breast cancer.},
  author={Paul E Goss},
  journal={Seminars in oncology},
  year={2004},
  volume={31 6 Suppl 12},
  pages={15-22}
}
Five years of tamoxifen is standard adjuvant therapy for hormone-sensitive early breast cancer, but women remain at appreciable risk of recurrence for many years following that therapy, and further tamoxifen does not appear to be beneficial. Trial MA.17 was designed to determine whether, following 5 years of tamoxifen, switching disease-free postmenopausal women to the aromatase inhibitor letrozole for 5 years improved disease-free survival compared with switching to placebo. The rationale was… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-5 of 5 extracted citations

Similar Papers

Loading similar papers…